Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: The incidence of slow flow after PCI was lower in the nicorandil group (13.6 vs. 27.3%, P < 0.04). ST segment resolution >50% was observed in 70.4 and 53.2% on nicorandil and placebo, respectively (P < 0.03). Patients treated with nicorandil had a lower peak creatine kinase level (3,137 +/- 2,577 vs. 4,333 +/- 3,608, P < 0.02). Upon Kaplan-Meier analysis, 5 years' freedom from MACEs was 86.4% in the nicorandil group and 74.0% in the placebo (P < 0.05). CONCLUSIONS: Adjunctive therapy with administration of intravenous nicorandil before reperfusion on AMI patients with stress hyperglycemia significantly improves epicardial flow and prevents the occurrence of severe microvascular reperfusion injury, resulting in better outcomes in these patients.
|
Authors | Hideki Ishii, Satoshi Ichimiya, Masaaki Kanashiro, Tetsuya Amano, Tatsuaki Matsubara, Toyoaki Murohara |
Journal | Diabetes care
(Diabetes Care)
Vol. 29
Issue 2
Pg. 202-6
(Feb 2006)
ISSN: 0149-5992 [Print] United States |
PMID | 16443860
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Blood Glucose
- Cardiotonic Agents
- Nicorandil
- Creatine Kinase
|
Topics |
- Aged
- Angioplasty, Balloon, Coronary
- Blood Glucose
- Cardiotonic Agents
(therapeutic use)
- Combined Modality Therapy
- Coronary Angiography
- Creatine Kinase
(blood)
- Diabetes Complications
- Disease-Free Survival
- Electrocardiography
- Female
- Follow-Up Studies
- Humans
- Hyperglycemia
(complications)
- Injections, Intravenous
- Male
- Middle Aged
- Myocardial Infarction
(therapy)
- Nicorandil
(therapeutic use)
- Proportional Hazards Models
- Prospective Studies
|